^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | melphalan (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
Published date:
07/21/2021
Excerpt:
In BRCA1/2 mutant patients, we showed a significant longer PFS compared to BRCA1/2 wild type patients (6.2 versus 2.6 months; hazard ratio (HR) 0.25, 95% confidence interval (CI) 0.10-0.61; p=0.002). Moreover, a trend was seen for BRCA1/2 mutants to have a better OS (25.9 versus 8.0 months; HR 0.38; 95% CI 0.12-1.19; p=0.097). Here, we report a considerable clinical activity of melphalan chemotherapy, more evident in a subset of BRCA1/2 mutated patients.
DOI:
10.3389/fonc.2021.716467
